selpercatinib
eli lilly
['3094', 'selpercatinib', 'cross tumor', 'libretto-001']
#asco22 abstract 3094 shows tumor agnostic efficacy of selpercatinib in #ret fusion cancers on libretto-001. orr 44% mdor 24.5m. fusions typically actionable across tumors. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him